Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Additive effect of bFGF and selenium on expansion and paracrine action of human amniotic fluid-derived mesenchymal stem cells

Fig. 3

Retention of phenotype and multipotency of AF-MSCs during bFGF and selenium treatments. a Flow cytometry analysis of AF-MSC surface markers. The MSC-specific markers CD13, CD29, CD44, CD71, CD90, and CD120a were observed, while the endothelial cell (CD31, CD106) and hematopoietic (CD15, CD33, CD34, CD45) markers were not expressed. b mRNA expression analysis of markers specific to MSCs and other cell types, such as neural stem cells (Musashi1, Sox1) and hematopoietic cells (CD133, CD34). c Adipogenic differentiation of AF-MSCs after 3 weeks of exposure to bFGF and selenium, alone or in combination (−/s, b/−, or b/s). d Osteogenic differentiation of AF-MSCs after 3 weeks of exposure to bFGF and selenium. e Chondrogenic differentiation of AF-MSCs after 3 weeks of exposure to bFGF and selenium. The differentiation of AF-MSCs into the three lineages was evaluated by Oil Red O, Von Kossa, and Alcian Blue staining. f Protein expression analysis of adipogenic, osteogenic, and chondrogenic markers in the differentiated AF-MSCs

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512